Literature DB >> 10729130

Kinetics of recombinant adeno-associated virus-mediated gene transfer.

A K Malik1, P E Monahan, D L Allen, B G Chen, R J Samulski, K Kurachi.   

Abstract

Recombinant adeno-associated virus (rAAV) vectors have been shown to be useful for efficient gene delivery to a variety of dividing and nondividing cells. Mechanisms responsible for the long-term, persistent expression of the rAAV transgene are not well understood. In this study we investigated the kinetics of rAAV-mediated human factor IX (hFIX) gene transfer into human primary myoblasts and myotubes. Transduction of both myoblasts and myotubes occured with a similar and high efficiency. After 3 to 4 weeks of transduction, rAAV with a cytomegalovirus (CMV) promoter showed 10- to 15-fold higher expression than that with a muscle-specific creatine kinase enhancer linked to beta-actin promoter. Factor IX expression from transduced myoblasts as well as myotubes reached levels as high as approximately 2 microgram of hFIX/10(6) cells/day. Southern blot analyses of high-molecular-weight (HMW) cellular genomic and Hirt DNAs isolated from rAAV/CMVhFIXm1-transduced cells showed that the conversion of single-stranded vector genomes to double-stranded DNA forms, but not the level of the integrated forms in HMW DNA, correlated with increasing expression of the transgene. Together, these results indicate that rAAV can transduce both proliferating and terminally differentiated muscle cells at about the same efficiency, that expression of transgenes increases linearly over their lifetime with no initial lag phase, and that increasing expression correlates with the appearance of double-stranded episomal rAAV genomes. Evidence showing that the rAAV virions can copackage hFIX, presumably nonspecifically, was also obtained.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10729130      PMCID: PMC111864          DOI: 10.1128/jvi.74.8.3555-3565.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  Lack of site-specific integration of the recombinant adeno-associated virus 2 genomes in human cells.

Authors:  S Ponnazhagan; D Erikson; W G Kearns; S Z Zhou; P Nahreini; X S Wang; A Srivastava
Journal:  Hum Gene Ther       Date:  1997-02-10       Impact factor: 5.695

2.  Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.

Authors:  D D Koeberl; I E Alexander; C L Halbert; D W Russell; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-18       Impact factor: 11.205

3.  Use of transdominant mutants of the origin-binding protein (UL9) of herpes simplex virus type 1 to define functional domains.

Authors:  A K Malik; S K Weller
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  High-level globin gene expression mediated by a recombinant adeno-associated virus genome that contains the 3' gamma globin gene regulatory element and integrates as tandem copies in erythroid cells.

Authors:  P W Hargrove; E F Vanin; G J Kurtzman; A W Nienhuis
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

6.  Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle.

Authors:  K R Clark; T J Sferra; P R Johnson
Journal:  Hum Gene Ther       Date:  1997-04-10       Impact factor: 5.695

7.  Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors.

Authors:  A F Shering; D Bain; K Stewart; A L Epstein; M G Castro; G W Wilkinson; P R Lowenstein
Journal:  J Gen Virol       Date:  1997-02       Impact factor: 3.891

8.  Recombinant adeno-associated virus for muscle directed gene therapy.

Authors:  K J Fisher; K Jooss; J Alston; Y Yang; S E Haecker; K High; R Pathak; S E Raper; J M Wilson
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

9.  Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.

Authors:  R W Herzog; J N Hagstrom; S H Kung; S J Tai; J M Wilson; K J Fisher; K A High
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

10.  Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.

Authors:  P D Kessler; G M Podsakoff; X Chen; S A McQuiston; P C Colosi; L A Matelis; G J Kurtzman; B J Byrne
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

View more
  11 in total

1.  TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo.

Authors:  Li Cheng; Przemyslaw Sapieha; Pavla Kittlerova; William W Hauswirth; Adriana Di Polo
Journal:  J Neurosci       Date:  2002-05-15       Impact factor: 6.167

2.  Genetic fate of recombinant adeno-associated virus vector genomes in muscle.

Authors:  Bruce C Schnepp; K Reed Clark; Dori L Klemanski; Christina A Pacak; Philip R Johnson
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

3.  Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo.

Authors:  H Nakai; S R Yant; T A Storm; S Fuess; L Meuse; M A Kay
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 4.  Cardiac gene therapy.

Authors:  Antoine H Chaanine; Jill Kalman; Roger J Hajjar
Journal:  Semin Thorac Cardiovasc Surg       Date:  2010

Review 5.  Cardiac gene therapy with SERCA2a: from bench to bedside.

Authors:  Judith K Gwathmey; Alexan I Yerevanian; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2010-11-18       Impact factor: 5.000

6.  Rapid transgene expression in multiple precursor cell types of adult rat subventricular zone mediated by adeno-associated type 1 vectors.

Authors:  Olivier Bockstael; Catherine Melas; Catherine Pythoud; Marc Levivier; Douglas McCarty; R Jude Samulski; Olivier De Witte; Liliane Tenenbaum
Journal:  Hum Gene Ther       Date:  2012-06-05       Impact factor: 5.695

7.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

8.  Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation.

Authors:  Ronen Beeri; Miguel Chaput; J Luis Guerrero; Yoshiaki Kawase; Chaim Yosefy; Suzan Abedat; Ioannis Karakikes; Charlotte Morel; Ashley Tisosky; Suzanne Sullivan; Mark D Handschumacher; Dan Gilon; Gus J Vlahakes; Roger J Hajjar; Robert A Levine
Journal:  Circ Heart Fail       Date:  2010-07-15       Impact factor: 8.790

Review 9.  Cystic fibrosis: exploiting its genetic basis in the hunt for new therapies.

Authors:  James L Kreindler
Journal:  Pharmacol Ther       Date:  2009-11-10       Impact factor: 12.310

10.  Lymphangiogenic gene therapy with minimal blood vascular side effects.

Authors:  Anne Saaristo; Tanja Veikkola; Tuomas Tammela; Berndt Enholm; Marika J Karkkainen; Katri Pajusola; Hansruedi Bueler; Seppo Ylä-Herttuala; Kari Alitalo
Journal:  J Exp Med       Date:  2002-09-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.